Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
| Title: | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study |
|---|---|
| Authors: | Gasbarrini A. |
| Contributors: | Qin, S.; Chan, S. L.; Gu, S.; Bai, Y.; Ren, Z.; Lin, X.; Chen, Z.; Jia, W.; Jin, Y.; Guo, Y.; Hu, X.; Meng, Z.; Liang, J.; Cheng, Y.; Xiong, J.; Ren, H.; Yang, F.; Li, W.; Chen, Y.; Zeng, Y.; Sultanbaev, A.; Pazgan-Simon, M.; Pisetska, M.; Melisi, D.; Ponomarenko, D.; Osypchuk, Y.; Sinielnikov, I.; Yang, T. -S.; Liang, X.; Chen, C.; Wang, L.; Cheng, A. -L.; Kaseb, A.; Vogel, A.; Zhang, M.; Xu, L.; Yuan, X.; Li, D.; Ying, J.; Zhang, J.; Zhang, T.; Gu, K.; He, Y.; Hao, P.; Jiang, D.; Zhang, S.; Xing, B.; Zhang, B.; Wang, D.; Zhai, X.; Liang, H.; Cybulska-Stopa, B.; Dvorkin, M.; Stroyakovskiy, D.; Nechaeva, M.; Yen, C. -J.; Su, W. -W.; Chen, Y. -H.; Bondarenko, I.; Yang, L.; Fang, W.; Gomez-Martin, C.; Ryu, M. -H.; Kim, H. -S.; Kim, J. -H.; Zarubenkov, O.; Orlova, R.; Poddubskaya, E.; Fadeeva, N.; Makarova, Y.; Chao, Y.; Hung, C. -H.; Neffa, M.; Vynnychenko, O.; Burgoyne, A.; Hao, C.; Mohr, R. U.; Diaz-Beveridge, R.; Feliu-Batlle, J.; Cubillo-Gracian, A.; Lee, A. -S.; Daniele, B.; Antonuzzo, L.; Sangiovanni, A.; Gasbarrini, Antonio; Scartozzi, M.; Ahn, M. S.; Oh, S. -Y.; Orlov, S.; Harputluoglu, H.; Oksuzoglu, B.; Hsu, C.; Rau, K. -M.; Krechkovskyi, O.; Yareshko, V.; Xiong, H.; Lee, F. -C.; Jiang, Y.; Gabayan, A.; Crow, M. |
| Publisher Information: | Elsevier B.V. |
| Publication Year: | 2023 |
| Collection: | Università Cattolica del Sacro Cuore: PubliCatt |
| Subject Terms: | n/a; Settore MEDS-05/A - Medicina interna |
| Description: | Background: Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Methods: This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions worldwide. Patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment were randomly assigned (1:1) to receive either camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily or sorafenib 400 mg orally twice daily. Randomisation was done via a centralised interactive response system. The primary endpoints were progression-free survival, as assessed by the blinded independent review committee per Response Evaluation Criteria in Solid Tumours version 1.1, and overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of the study drugs. We report the findings from the prespecified primary analysis for progression-free survival and interim analysis for overall survival. This study is registered with ClinicalTrials.gov (NCT03764293). Findings: Between June 28, 2019, and March 24, 2021, 543 patients were randomly assigned to the camrelizumab–rivoceranib (n=272) or sorafenib (n=271) group. At the primary analysis for progression-free survival (May 10, 2021), median follow-up was 7·8 months (IQR 4·1–10·6). Median progression-free survival was significantly improved with camrelizumab–rivoceranib versus sorafenib (5·6 months [95% CI 5·5–6·3] vs 3·7 months [2·8–3·7]; hazard ratio [HR] 0·52 [95% CI 0·41–0·65]; ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/37499670; info:eu-repo/semantics/altIdentifier/wos/WOS:001094086600001; volume:402; issue:10408; firstpage:1133; lastpage:1146; numberofpages:14; issueyear:2023; journal:THE LANCET; https://hdl.handle.net/10807/302087 |
| DOI: | 10.1016/S0140-6736(23)00961-3 |
| Availability: | https://hdl.handle.net/10807/302087; https://doi.org/10.1016/S0140-6736(23)00961-3 |
| Accession Number: | edsbas.C726FEF |
| Database: | BASE |